Mirati Therapeutics Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Mirati Therapeutics han disminuido a una tasa media anual de -35.9%, mientras que en la industria Biotechs los beneficios crecieron en un 12.7% anualmente. Los ingresos han ido creciendo a una tasa media de 34.7% al año.

Información clave

-35.9%

Tasa de crecimiento de los beneficios

-26.2%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	34.7%
Rentabilidad financiera	-76.7%
Margen neto	-1,900.7%
Última actualización de beneficios	30 Sep 2023

Actualizaciones de resultados anteriores recientes

Recent updates

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Oct 05

Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?

Jun 22

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

May 17

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Feb 01

Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates

Dec 09

We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Oct 08

Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Sep 11

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Aug 08

Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years

Jun 21

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Mirati Therapeutics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:MRTX Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Sep 23	38	-726	292	0
30 Jun 23	27	-738	281	0
31 Mar 23	19	-737	259	0
31 Dec 22	12	-741	240	0
30 Sep 22	12	-738	213	0
30 Jun 22	78	-645	187	0
31 Mar 22	73	-634	162	0
31 Dec 21	72	-582	137	0
30 Sep 21	74	-483	118	0
30 Jun 21	13	-491	104	0
31 Mar 21	13	-407	94	0
31 Dec 20	13	-358	83	0
30 Sep 20	12	-329	70	0
30 Jun 20	2	-296	61	0
31 Mar 20	2	-259	51	0
31 Dec 19	3	-213	43	0
30 Sep 19	6	-169	37	0
30 Jun 19	5	-142	31	0
31 Mar 19	5	-125	26	0
31 Dec 18	13	-98	22	0
30 Sep 18	9	-88	18	0
30 Jun 18	9	-77	16	0
31 Mar 18	9	-67	15	0
31 Dec 17	0	-70	13	0
30 Sep 17	0	-72	14	13
30 Jun 17	0	-75	15	30
31 Mar 17	0	-79	15	48
31 Dec 16	0	-83	15	0
30 Sep 16	0	-82	15	67
30 Jun 16	0	-81	16	66
31 Mar 16	0	-75	16	59
31 Dec 15	0	-65	16	49
30 Sep 15	0	-57	16	41
30 Jun 15	0	-46	15	33
31 Mar 15	0	-42	14	29
31 Dec 14	0	-44	13	26
30 Sep 14	0	-45	12	23
30 Jun 14	0	-65	12	22
31 Mar 14	0	-62	11	19
31 Dec 13	0	-53	11	20
30 Sep 13	0	-48	10	20
30 Jun 13	0	-24	8	19

Ingresos de calidad: MRTX actualmente no es rentable.

Margen de beneficios creciente: MRTX actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: MRTX no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 35.9% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de MRTX en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: MRTX no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-8.9%).

Rentabilidad financiera

Alta ROE: MRTX tiene una rentabilidad financiera negativa (-76.69%), ya que actualmente no es rentable.

Mirati Therapeutics Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: EPS exceeds analyst expectations

Mirati Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Mirati Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Mirati Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Mirati Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Recent updates

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Price target increased by 9.7% to US$60.00

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

New major risk - Share price stability

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Insufficient new directors

Mirati Therapeutics, Inc. Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers Through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Second quarter 2023 earnings: EPS exceeds analyst expectations

Mirati Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of Krazati (Adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with A Krasg12c Mutation

Price target decreased by 8.0% to US$60.64

New minor risk - Insider selling

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?

Chief Financial Officer recently sold US$172k worth of stock

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO(R)

Insufficient new directors

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Consensus revenue estimates increase by 23%

Consensus revenue estimates decrease by 28%

Mirati Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

CEO & Director recently sold US$135k worth of stock

Mirati Therapeutics, Inc. Announces U.S. Food and Drug Administration Clears the Investigational New Drug (Ind) Application of MRTX1133

Founder recently sold US$170k worth of stock

Executive VP & Chief Scientific Officer recently sold US$104k worth of stock

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

Mirati Therapeutics, Inc. Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates

Price target decreased to US$91.40

Executive VP & Chief Scientific Officer recently sold US$156k worth of stock

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mirati Therapeutics, Inc. Announces Update for the Phase 3 SAPPHIRE Study

Founder exercised options and sold US$5.7m worth of stock

Mirati Therapeutics Reportedly Seen as Takeover Target Once Again

Consensus revenue estimates increase by 48%

Mirati Therapeutics, Inc. Announces Management Changes

Mirati Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Mirati: A Potential Blockbuster Stock, Will Need Patience

Mirati Therapeutics, Inc. Presents Late-Breaking Adagrasib Monotherapy and Combination

Mirati jumps 11% as Amgen meets key goal for rival cancer drug

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 15%

Mirati gains as Amgen posts new combination data for rival cancer drug

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Mirati Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years

Mirati Therapeutics, Inc. Announces Results of A Prospective Analysis from the Phase 1B Cohort of the KRYSTAL-1

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta